Results 201 to 210 of about 160,917 (252)

Research on unintroduced new drugs in South Korea from 2011 to 2020: approaches to prioritization and strategy. [PDF]

Transl Clin Pharmacol
Jeon H, Park SI, Lee SW, Kim TE, Shin KH, Song I, Chung H, Bae B, Baik S, Gu N.   +9 more
europepmc   +1 more source

Cost-utility analysis of ropeginterferon alfa-2b to manage low-risk patients with polycythemia vera as compared to phlebotomy only in the Austrian healthcare system. [PDF]

Ann Hematol
Walter E, Torelli F, Barbui T.
europepmc   +1 more source

Which clinical trial designs and statistical approaches have been used in assessments of orphan maintenance by the European Medicines Agency between 2012 and 2022? A cross-sectional study. [PDF]

BMJ Open
Windfuhr F, Larsson K, Framke T, Lasch F.   +3 more
europepmc   +1 more source

Bedside manufacturing as the next step in personalized medicine: medical progress and legal challenges. [PDF]

J Law Biosci
El Saadany T, Seitz C, Bräm C, Szucs T.
europepmc   +1 more source

Mode 2 knowledge production: evidence from orphan drug networks

Science and Public Policy, 2007
This paper seeks to contribute to the understanding of public participation in the process of science policy-making and the lay public's contribution to scientific knowledge production.
Helen Crompton
semanticscholar   +6 more sources

Europe finally agrees to encourage orphan-drug production

The Lancet, 2000
Arthur Rogers
semanticscholar   +4 more sources